ryzumvi
Ryzumvi (Phentolamine Mesylate) is an alpha-adrenergic blocker used to treat Extravasation of Diagnostic and Therapeutic Materials, Malignant Hypertension, Necrosis.
Phentolamine Mesylate · by Famygen Life Sci
Key facts
- Active ingredient
- Phentolamine Mesylate
- Drug class
- Alpha-Adrenergic Blocker
- Form
- Drops
- Strength
- Phentolamine Mesylate EQ 0.75% Base
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Famygen Life Sci
- FDA application
- NDA217064
What is Ryzumvi?
From the FDA label:RYZUMVI (phentolamine ophthalmic solution) 0.75% is a sterile, clear and colorless solution for topical ophthalmic use containing 1% phentolamine mesylate (equivalent to 0.75% phentolamine). The product does not contain an anti-microbial preservative. The chemical name of phentolamine mesylate is 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol; methanesulfonic acid (parent phentolamine: [3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol]) and the molecular formula is C 18 H 23 N 3 O 4 S (parent C 17 H 19 N 3 O). The molecular weight of phentolamine mesylate is 377.46 and the chemical structure is: Each mL of RYZUMVI contains phentolamine mesylate 10 mg as the active ingredient (equivalent to 7.5 mg phentolamine as the free base). Inactive ingredients are mannitol, sodium acetate trihydrate, and water for injection. Hydrochloric acid and/or sodium hydroxide are added to adjust pH (4.5 to 5.5), and the solution is overlaid with nitrogen. chemical structure
How to use
Adults and Pediatric Patients Aged 12 Years or Older: Instill 1 or 2 drops in each dilated eye following the completion of the ophthalmic examination or procedure. If 2 drops are instilled, the second drop should be administered 5 minutes after the first drop. Pediatric Patients Aged 3 to 11 Years: Instill 1 drop in each dilated eye following the completion of the ophthalmic examination or procedure. One single-patient-use vial can be used to dose each dilated eye. Discard the single-patient-use vial immediately after use. • Adults and Pediatric Patients Aged 12 Years and Older: Instill 1 to 2 drops in each dilated eye following the completion of the ophthalmic examination or procedure to reverse mydriasis. ( 2 ) • Pediatric Patients Aged 3 to 11 Years: Instill 1 drop in each dilated eye following the completion of the ophthalmic examination or procedure to reverse mydriasis. ( 2 )
Side effects
The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. RYZUMVI was evaluated in 642 subjects in clinical trials across various subject populations. The most common ocular adverse reactions reported in > 5% of subjects were instillation site discomfort including pain, stinging, and burning (16%) and conjunctival hyperemia (12%). The only non-ocular adverse reaction reported in > 5% of subjects was dysgeusia (6%).
Warnings
Important safety information
Uveitis : RYZUMVI is not recommended to be used in patients with active ocular inflammation. ( 5.1 ) 5.1 Uveitis RYZUMVI is not recommended when active ocular inflammation (e.g., iritis) is present because adhesions (synechiae) may form between the iris and the lens. 5.2 Potential for Eye Injury or Contamination To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface. 5.3 Use with Contact Lenses Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.
Who should not take Ryzumvi
None. None. ( 4 )
Overdose — what happens if you take too much
No deaths due to acute poisoning with phentolamine have been reported. Overdosage with parenterally administered phentolamine is characterized chiefly by cardiovascular disturbances, such as arrhythmias, tachycardia, hypotension, and possibly shock. In addition, the following might occur: excitation, headache, sweating, visual disturbances, nausea, vomiting, diarrhea, or hypoglycemia. There is no specific antidote; treatment consists of appropriate monitoring and supportive care. Substantial decreases in blood pressure or other evidence of shock-like conditions should be treated vigorously and promptly.
U.S. Poison Control: call or text 1-800-222-1222 (free, 24/7). In an emergency call 911. From the FDA label; not medical advice.
Drug class
How this class works, per Alpha-Blockers - StatPearls - NCBI Bookshelf.
May treat (source: NIH RxClass)
See how Ryzumvi ranks — best-rated alpha-adrenergic blocker for:
Dosage forms
Drops
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Ryzumvi treat?
- Ryzumvi (Phentolamine Mesylate) may be used to treat extravasation of diagnostic and therapeutic materials, malignant hypertension, necrosis, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How does Ryzumvi work?
- Ryzumvi is a alpha-adrenergic blocker. Alpha-adrenergic blockers block the alpha-1 receptors that adrenaline-like signals use to tighten muscle in blood vessels and the prostate. This relaxes those muscles, lowering blood pressure and easing urine flow in men with an enlarged prostate.
- Is there a coupon or discount for Ryzumvi?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Ryzumvi. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Ryzumvi?
- Ryzumvi is marketed by Famygen Life Sci. You can see Famygen Life Sci's full profile, rating, and other products on pharmaranks.
- Is Ryzumvi a brand-name or generic drug?
- Ryzumvi is a brand-name product with the active ingredient Phentolamine Mesylate.
- Is Ryzumvi available over the counter?
- No. Ryzumvi is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Ryzumvi come in?
- Ryzumvi is currently marketed as drops, per the FDA's National Drug Code Directory.
- What class of drug is Ryzumvi?
- Ryzumvi is classified as alpha-adrenergic blocker, per the FDA's Established Pharmacologic Class.
- Is Ryzumvi FDA-registered?
- Ryzumvi is on record with the U.S. FDA under application number NDA217064. You can verify this on its official FDA label.
- Is Ryzumvi safe?
- There's no single safe-or-not verdict, and we don't yet have a composite recall-safety score for Ryzumvi. Review its FDA-label side effects and warnings below, and always consult a licensed professional.
- What are the side effects of Ryzumvi?
- Ryzumvi's side effects are taken directly from its FDA label. From the label: The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.… Both common and serious reactions are documented in full on this page. This is general reference from the FDA, not medical advice — always consult a professional.
Clinical content sourced from the FDA label via openFDA (U.S. FDA). View the FDA label on DailyMed → Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
Reviews
No reviews yet. Be the first to write one.
People also viewed
cardura
Doxazosin Mesylate
tamsulosin hydrochloride
Tamsulosin Hydrochloride
cardura xl
Doxazosin Mesylate
minipress
Prazosin Hydrochloride
coreg
Carvedilol
coreg cr
Carvedilol Phosphate
Compare Ryzumvi head-to-head
More alpha-adrenergic blocker drugs
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
ryzumvi
New